← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
76	76 Marker Therapeutics MRKR $15M	5	-1	-17%	$75K
77	CYAD 77 DELISTED Celyad Oncology SA American Depositary Shares CYAD	4	-2	-33%	$16M
78	78 DELISTED Scorpius Holdings, Inc. SCPX	3	0	0%	$1.9M
79	79 Adicet Bio ACET $47.9M	–	–	–	–
80	ACHL 80 DELISTED Achilles Therapeutics ACHL	–	–	–	–
81	81 DELISTED Arcellx ACLX	–	–	–	–
82	82 Adaptive Biotechnologies ADPT $4.09B	–	–	–	–
83	AKUS 83 DELISTED Akouos Inc AKUS	–	–	–	–
84	84 Allogene Therapeutics ALLO $460M	–	–	–	–
85	85 ALPS Group Inc ALPS $56.6M	–	–	–	–
86	86 Artiva Biotherapeutics ARTV $294M	–	–	–	–
87	87 Autolus Therapeutics AUTL $458M	–	–	–	–
88	88 BridgeBio Pharma BBIO $13.1B	–	–	–	–
89	89 BioCardia BCDA $13.9M	–	–	–	–
90	90 Beam Therapeutics BEAM $2.51B	–	–	–	–
91	91 Bionano Genomics BNGO $16.1M	–	–	–	–
92	92 Burning Rock Biotech BNR $165M	–	–	–	–
93	93 BioRestorative Therapies BRTX $1.95M	–	–	–	–
94	94 Cabaletta Bio CABA $264M	–	–	–	–
95	95 Candel Therapeutics CADL $682M	–	–	–	–
96	96 Caris Life Sciences CAI $8.81B	–	–	–	–
97	97 CAMP4 Therapeutics CAMP $216M	–	–	–	–
98	98 Cibus CBUS $101M	–	–	–	–
99	99 Celularity CELU $42.8M	–	–	–	–
100	100 Creative Medical Technology CELZ $6.03M	–	–	–	–